1 / 1

J-CHF

J-CHF. Death or hospitalization: 22.9% of 2.5 mg, 19.0 % of 5 mg, and 21.2% of 20 mg group (p = 0.61 for 2.5 vs. 5 mg, p = 0.99 for 2.5 vs. 20 mg) All-cause deaths (n): 9, 7, 8 (p = NS), respectively Hospitalization for cardiovascular diseases (n): 8, 10, 5 (p = NS), respectively

esben
Télécharger la présentation

J-CHF

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. J-CHF Death or hospitalization: 22.9% of 2.5 mg, 19.0 % of 5 mg, and 21.2% of 20 mg group (p = 0.61 for 2.5 vs. 5 mg, p = 0.99 for 2.5 vs. 20 mg) All-cause deaths (n): 9, 7, 8 (p = NS), respectively Hospitalization for cardiovascular diseases (n): 8, 10, 5 (p = NS), respectively Hospitalization for heart failure (n): 21, 14, 18 (p = NS), respectively Trial design: Patients with chronic stable heart failure were randomized to carvedilol 2.5 mg daily (n = 119), 5 mg daily (n = 121), or 20 mg daily (n = 120). Mean follow-up, 3 years. Results (p = NS) (p = NS) Conclusions • Among patients with chronic stable heart failure, there was no apparent difference in clinical outcomes at a mean of 3 years of follow-up among three doses of carvedilol • This study was significantly underpowered to detect a difference in important clinical outcomes Death or hospitalization (%) Number for all-cause deaths (n) 2.5 mg 5 mg 20 mg Presented by Dr. Mosatsugu Hori at AHA 2009

More Related